Drug updated on 5/6/2024
| Dosage Form | Injection (intravenous; 100 mg) |
| Drug Class | Hydrolytic lysosomal glycogen-specific enzymes |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency)
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Nexviazyme (avalglucosidase alfa-ngp) Prescribing Information. | 2023 | Genzyme Corporation Cambridge, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Enzyme replacement therapy for late-onset Pompe disease. | 2023 | The Cochrane Database of Systematic Reviews |